Logo
x

Search

Subscribe Now

(trastuzumab emtansine)

Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treat

Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER...

  • November 15, 2019
Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)

Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)

  • December 6, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.